LADOSTIGIL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H20N2O2
Molecular Weight	272.3422
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1

InChI

InChIKey=LHXOCOHMBFOVJS-OAHLLOKOSA-N

InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3/t15-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H20N2O2
Molecular Weight	272.3422
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67423264 | https://www.ncbi.nlm.nih.gov/pubmed/11205137 | https://www.ncbi.nlm.nih.gov/pubmed/22280345

LADOSTIGIL, a rasagiline derivative, is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor with neuroprotective properties. It also acts as an irreversible brain monoamine oxidases inhibitor. It is under development for the treatment of neurodegenerative disorders like dementia and Alzheimer's disease.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.	2010-06	22110336
The role of rasagiline in the treatment of Parkinson's disease.	2010-05-25	20517484
The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.	2010	21103012
Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk.	2009-12-01	19729413
Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.	2009-08-12	19672295
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?	2009-04-02	19461897
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.	2009-02	18751929
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.	2009-01	19110207
The neurotrophic and neuroprotective effects of psychotropic agents.	2009	19877500
The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.	2008-09-25	18598687
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.	2008-08	19043511
The neuroprotective mechanism of action of the multimodal drug ladostigil.	2008-05-01	18508575
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.	2007-12	18077571
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.	2007-10	17635668
Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.	2007-08	17580085
Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.	2007-03	17123555
The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection.	2007-02	17115941
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.	2006-12	17197368
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.	2006-12	17168653
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.	2006-10	16935943
Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression.	2006	17017566
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.	2005-10	16086033
Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats.	2005-08	15830235
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.	2005-02	15621213
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.	2004-12-02	15573406
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.	2004-03-25	15027867
Protein 4.1N is required for translocation of inositol 1,4,5-trisphosphate receptor type 1 to the basolateral membrane domain in polarized Madin-Darby canine kidney cells.	2003-02-07	12444087

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:30:12 GMT 2025` Edited by `admin` on `Wed Apr 02 09:30:12 GMT 2025`
Record UNII	SW3H1USR4Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TV-3326 FREE BASE

Preferred Name

English

LADOSTIGIL

Official Name

English

ladostigil [INN]

Common Name

English

(3R)-3-(PROP-2-YN-1-YLAMINO)-2,3-DIHYDRO-1H-INDEN-5-YL ETHYL(METHYL)CARBAMATE

Systematic Name

English

CARBAMIC ACID, ETHYL(METHYL)-, (3R)-2,3-DIHYDRO-3-(2-PROPYNYLAMINO)-1H-INDEN-5-YL ESTER

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C667